ImmunityBioIBRX

• Phase 2HPV 양성 구인두암 백신·항암제 병용 임상시작 전Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
  84%
• Phase 2림프구감소증 동반 패혈증 환자 대상 NAI 치료 임상시작 전NAI for Sepsis With Persistent Lymphopenia
  75%
• Phase 3진행성 비소세포폐암 대상 N-803 3제 병용요법 임상모집 중ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
  35%
• Phase 1재발성/불응성 비호지킨 림프종 환자 대상 치료 연구모집 중Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
  45%
• Phase 1ALT-803·BCG 병용 비근침습 방광암 임상진행 중A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
  58%
• Phase 2CD19 t-haNK 저등급 비호지킨 림프종 병용 치료 임상시작 전Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
  56%
• Phase 2재발성 B세포 비호지킨 림프종 치료 연구모집 중Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
  58%
• Phase 2기존 면역항암제 치료 실패 암 환자 병용 임상진행 중QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
  59%
• Phase 2진행성 췌장암 병용 면역항암치료 유효성 평가진행 중Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
  12%
• Phase 1자가 유래 면역세포 M-CENK 진행성 고형암 임상진행 중QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
  76%
• Phase 2M-CENK 세포치료제 및 N-803 난소암 병용 2상모집 중A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
  72%
• Phase 1IBRX-042 HPV 관련 암 치료 임상진행 중IBRX-042 In Participants With HPV-Associated Tumors
  45%

성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요. 예측이 없는 임상 2건은 생략했어요.